Bausch + Lomb Corporation Share Price Toronto S.E.

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Market Closed - Toronto S.E. 11:23:02 26/06/2024 pm IST 5-day change 1st Jan Change
20.2 CAD -0.74% Intraday chart for Bausch + Lomb Corporation -0.83% -10.90%

Financials

Sales 2024 * 4.66B 6.38B 389B Sales 2025 * 4.94B 6.77B 413B Capitalization 5.2B 7.11B 434B
Net income 2024 * -236M -323M -19.7B Net income 2025 * -61M -83.5M -5.09B EV / Sales 2024 * 2 x
Net Debt 2024 * 4.12B 5.64B 344B Net Debt 2025 * 3.8B 5.21B 317B EV / Sales 2025 * 1.82 x
P/E ratio 2024 *
-24.9 x
P/E ratio 2025 *
-109 x
Employees 13,300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 11.5%
More Fundamentals * Assessed data
Dynamic Chart
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care" MT
Bausch + Lomb Corporation Announces the U.S. Introduction of Bausch + Lomb Infuse for Astigmatism Daily Disposable Contact Lenses CI
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States MT
Bausch + Lomb Corporation Launches Blink? NutriTears® Clinically Proven Nutritional Supplement for Dry Eyes in the United States CI
Bausch + Lomb Corporation Approves Election of Gary Hu as Director CI
Bausch + Lomb's New Intraocular Lens Approved by Health Canada MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens MT
Bausch + Lomb Corporation Receives Health Canada Approval for Envista Envy?? Full Visual Range Intraocular Lens CI
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade MT
Morgan Stanley Upgrades Bausch + Lomb to Overweight From Equalweight, Raises Price Target to $18 From $16 MT
RBC Capital Reviews Bausch + Lomb's Q1 Results MT
Deutsche Bank Adjusts Bausch + Lomb Price Target to $14 From $18, Maintains Hold Rating MT
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year MT
Bausch + Lomb Q1 Loss Widens, Revenue Increases MT
Transcript : Bausch + Lomb Corporation, Q1 2024 Earnings Call, May 01, 2024
More news
1 day-0.74%
1 week-0.83%
Current month-4.08%
1 month-1.99%
3 months-12.55%
6 months-3.67%
Current year-10.90%
More quotes
1 week
20.11
Extreme 20.11
20.80
1 month
19.91
Extreme 19.91
21.53
Current year
18.11
Extreme 18.11
23.87
1 year
18.11
Extreme 18.11
28.96
3 years
15.95
Extreme 15.95
28.96
5 years
15.95
Extreme 15.95
28.96
10 years
15.95
Extreme 15.95
28.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 06/23/06
Director of Finance/CFO 51 01/22/01
Chief Tech/Sci/R&D Officer 57 31/22/31
Members of the board TitleAgeSince
Chief Executive Officer 56 06/23/06
Director/Board Member 68 01/22/01
Director/Board Member 44 21/22/21
More insiders
Date Price Change Volume
26/24/26 20.2 -0.74% 1,103
25/24/25 20.35 -0.20% 954
24/24/24 20.39 -1.97% 1,322
21/24/21 20.8 +1.17% 20,681
20/24/20 20.56 +0.93% 10,103

Delayed Quote Toronto S.E., June 26, 2024 at 11:23 pm IST

More quotes
Bausch + Lomb Corporation is an eye health company. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. The Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
14.77 USD
Average target price
18.71 USD
Spread / Average Target
+26.70%
Consensus